PASITHEA THERAPEUTICS CORP (KTTA) Stock News
NASDAQ:KTTA - Nasdaq - US70261F2020 - Common Stock - Currency: USD
KTTA Latest News, Press Releases and Analysis
Thursday's session: top gainers and losers
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Thursday's session: gap up and gap down stocks
Traders are paying attention to the gapping stocks in Thursday's session. Let's dive into which stocks are experiencing notable gaps.
Which stocks are moving before the opening bell on Thursday?
As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
These stocks are moving in today's after hours session
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
Pasithea's PAS-004 Phase 1 trial advances to 22mg dose with no DLTs or rash, reinforcing its safety profile as a next-gen MEK inhibitor for NF1 and...
Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4
Pasithea opens EU trial sites for PAS-004, doses Cohort 4, and plans interim safety data in Q1 2025....
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
Pasithea Tx' PAS-004 Phase 1 trial advances to a 15mg dose after no toxicities or rash observed, highlighting its safety and differentiated profile....
Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology...
Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
Pasithea Therapeutics' PAS-004 shows positive Phase 1 data: well-tolerated, no toxicities, promising efficacy in NF1 and MAPK-driven cancers....
Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies
Pasithea completes chronic toxicity studies for PAS-004, showing safety and potential for long-term use in NF1 and cancer treatment; Phase 1 trial ongoing...
Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board
Pasithea Tx appoints Dr. Rebecca Brown, an expert in Neurofibromatosis and Director at Mount Sinai, to its Scientific Advisory Board to aid in PAS-004....
Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Pasithea Therapeutics will present at H.C. Wainwright’s Global Investment Conference, highlighting PAS-004 development for NF1 and cancer....
KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q2 2024
Pasithea Therapeutics just reported results for the second quarter of 2024.
KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pasithea Therapeutics (NASDAQ:KTTA) just reported results for the second quarte...
KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q4 2023
Pasithea Therapeutics just reported results for the fourth quarter of 2023.
Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial
Pasithea Therapeutics completes enrollment and initial dosing of Cohort 2 in its Phase 1 trial of PAS-004, with interim safety data expected in Q3 2024....
Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting
Pasithea to present preclinical data at ASCO 2024 showing PAS-004 superior inhibition of NRAS cancer cells and xenograft tumors compared to current...
KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q1 2024
Pasithea Therapeutics just reported results for the first quarter of 2024.
Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024....
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004
Pasithea Tx activates four U.S. sites for Phase 1 Trial of its next-gen MEK inhibitor, aiming to assess safety, efficacy, and biomarker data....
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are worth checking out on Friday as we get into all of the biggest news affecting shares this morning!
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position
Pasithea Therapeutics unveils crystalline PAS-004, extending IP protection to 2045 for CNS disorder treatments....
Pasithea conducts 1-for-20 reverse stock split, gets FDA okay for study (NASDAQ:KTTA)
Pasithea Therapeutics (KTTA) has conducted a 1-for-20 reverse stock split and received FDA clearance for Phase 1 study of its oncology drug PAS-004. Read more here.
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
Pasithea's IND for PAS-004, a novel MEK inhibitor, is FDA-approved for Phase 1 trials in advanced cancer, starting Q1 2024 with early results by Q3....
Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023
Pasithea Therapeutics (Nasdaq: KTTA) adjourns stockholder meeting again to Dec 29 for voting on charter amendments, after partial adjournment on Dec 19....
Pasithea Therapeutics Announces Results from 2023 Annual Meeting
Disclosure related to the annual meeting of Pasithea Therapeutics (Nasdaq: KTTA)...